Association between thyroid dysfunction and venous thromboembolism: A systematic review and meta-analysis : Medicine

Journal Logo

Research Article: Systematic Review and Meta-Analysis

Association between thyroid dysfunction and venous thromboembolism: A systematic review and meta-analysis

Wang, Yunmeng MMa; Ding, Chaowei MMb; Guo, Chang MMb; Wang, Jingru MMa; Liu, Suyun MDa,*

Author Information
Medicine 102(11):p e33301, March 17, 2023. | DOI: 10.1097/MD.0000000000033301


1. Introduction

Venous thromboembolism (VTE) includes deep vein thrombosis, and pulmonary embolism. Tumors, surgery, immobilization, advanced age, obesity, smoking habit, respiratory failure, rheumatic immune disease, and other factors leading to blood stasis, hypercoagulable state, and endothelial cell injury can increase the risk of VTE.[1] Deep vein thrombosis and pulmonary embolism are usually associated with poor prognosis in cardiovascular inpatients, and early diagnosis and intervention of VTE have become the most common and important measures to prevent in-hospital death.[2]

Thyroid dysfunction, including (subclinical) hyperthyroidism and (subclinical) hypothyroidism, is a very common endocrine disorder that is usually defined according to thyroid-stimulating hormone, triiodothyronine, free thyroxine, free triiodothyronine, and free thyroxine levels.[3] Thyroid dysfunction is often accompanied by abnormalities in the coagulation and fibrinolysis systems.[4,5] It is reported that hypercoagulable and hypofibrinolytic states usually characterize hyperthyroidism, while hypothyroidism shows hypocoagulable and hyperfibrinolytic states. Abnormalities in coagulation and fibrinolytic factors have been shown to contribute to the development of thrombosis. However, it is unclear whether the presence of thyroid dysfunction increases the risk of thrombosis. In some clinical observational studies, patients with (subclinical) hyperthyroidism and (subclinical) hypothyroidism were found to have an increased risk of VTE formation. Thyroid diseases with opposite trends in hormone levels may require a more refined assessment of patient coagulation and VTE risk during clinical diagnosis and treatment. Therefore, there is an urgent need to know the risk of VTE in patients with thyroid dysfunction.

This study aimed to assess the risk of VTE in patients with thyroid dysfunction compared with a euthyroid population and to comprehensively investigate whether patients with thyroid dysfunction have an increased risk of VTE by identifying all available cohort and case-control studies and summarizing the results.

2. Methods

Our study complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.[6] A protocol was registered with PROSPERO, registration number CRD42022369938.

2.1. Literature retrieval

Three reviewers (Y.W., C.D., and C.G.) independently searched PubMed, EMBASE, China national knowledge infrastructure, and the Cochrane Library databases from the time of database establishment to 01 October 2022. The search terms were derived from terms related to “(subclinical) hypothyroidism,” “(subclinical) hyperthyroidism,” “venous thromboembolism,” “pulmonary embolism,” and “deep vein thrombosis” without language restrictions. The retrieval strategy is shown in Supplemental Digital Content (Table S1,

2.2. Inclusion and exclusion criteria

Inclusion criteria: Case-control or cohort design studies. Data on the association between thyroid dysfunction and VTE were reported. VTE was defined based on the definitive diagnosis (by lower-limb venous compression ultrasonography, computed tomography, ventilation-perfusion scan, angiography, or autopsy), or VTE’s diagnostic code could be extracted from medical records. Thyroid dysfunction was defined based on thyroid-stimulating hormone, free triiodothyronine, free thyroxine, or patients with clear medical records on thyroid dysfunction (hyperthyroidism, hypothyroidism, subclinical hyperthyroidism, subclinical hypothyroidism).

Exclusion criteria: Duplicate, non-English or non-Chinese, non-human studies, case reports, reviews, meta-analyses, or conference reports. If there were multiple publications in the same cohort, only the publication with the latest statistical data would be used. Cases complicated with other diseases such as tumors. Literature without full-text access.

2.3. Data extraction and quality assessment

Two authors (Y.W. and C.D.) independently screened abstracts and performed a full-text review to check eligibility for inclusion. A third independent author (C.G.) was consulted to reach a consensus when there was controversy. The following data were extracted from the included studies: author, year, country, study design (case-control study or cohort study), baseline characteristics of patients, sample size, and risk of VTE (HR, RR, OR). OR was calculated from the original data if not provided directly. Study quality was assessed by Newcastle-Ottawa Score (NOS),[7] and studies with NOS scores≥7 were considered of high quality.

2.4. Data pooling and analysis

The association between thyroid dysfunction and VTE was quantified with OR.[8] These data were also pooled together by random-effects or fixed-effects meta-analysis to measure the effect of thyroid dysfunction on VTE risk. Integrated analysis of each study was assessed by forest plots. Statistical heterogeneity of the included studies was evaluated using the I2 statistic. A random-effects model was used when heterogeneity was significant (P < .1 or I2 > 50%); otherwise, a fixed-effects model[9] was employed. A sensitivity test was performed to evaluate whether a single study could significantly affect the pooled results. Funnel plot, Begg and Egger tests were used to evaluate the publication bias. If there was significant publication bias, the trim-and-fill method was introduced to evaluate the difference in the results.[10] All analyses mentioned above were performed in STATA statistical software, version 15.1.

3. Results

3.1. Literature retrieval

We retrieved 2418 articles according to the retrieval strategy, of which 289 were duplicate studies. Two thousand and eighty articles were excluded based on the information given in the title and abstract. For the remaining 32 articles, 10 articles with 15 studies were finally included after reviewing the full text for a detailed evaluation. The screening process is illustrated in Figure 1.

Figure 1.:
Flow chart of study selection.

3.2. Basic characteristics of included studies

Fifteen studies in 10 articles with a total of 941,731,087 participants were included. Eight studies reported the risk of VTE in patients with (subclinical) hyperthyroidism, of which 7 were cohort studies[11–16] and 1 was a case-control study.[17] Regarding study location, 6 studies were conducted in Europe,[11–13,15,17] 1 in North America[16] and 1 in China.[14] One study involved women only.[16] The risk of VTE in patients with (subclinical) hypothyroidism was reported in the other 7 studies included, of which 6 were cohort studies[13,18–20] and 1 was a case-control study.[17] Five studies were conducted in Europe[13,17,18,20] and 2 studies were conducted in China.[19] Three studies were conducted only in women,[17,19,20] 2 studies only in men,[19,20] and the remaining studies involved both genders. The basic characteristics of the included studies are shown in Table 1.

Table 1 - Characteristics of studies included in this meta-analysis.
Author, year Country Study design Types of thyroid dysfunction Thyroid dysfunction confirmation Population (n) Events (n) Age Gender Multi-variates analysis NOS
Cases Comparators Male Female
Danescu, 2009 USA Retrospective cohort Hypothyroidism ICD-9-CM 927,651,000 10,497,000 NA NA 373,581,000 554,070,000 NA 5
Dekkers 2017 Denmark Retrospective cohort Hyperthyroidism ICD-8,10 932,913 85,856 NA NA 168,820 764,093 Age, sex, calendar years and other co-morbidities 8
Hizkiyahu, 2022 Canada Retrospective cohort Hyperthyroidism ICD-9-CM 9,096,788 NA NA NA 9,096,788 Age, race, type of health insurance, obesity, smoking and other co-morbidities 8
Lerstad, 2016 Norway Prospective cohort (Subclinical) hyperthyroidism TSH < 0.5 mlU/L 17,061 262 62 ± 8 61 ± 12 7453 9608 BMI and smoking 8
(Subclinical) hypothyroidism TSH > 5.0 mlU/L 17,491 271 65 ± 10 61 ± 12 7664 9827 BMI and smoking
Lin, 2010 China Retrospective cohort Hyperthyroidism ICD-9-CM 53,418 8903 40.7 ± 14.9 40.5 ± 15.5 12,312 41,106 Age, sex, oral anticoagulant use, monthly income, geographic region, and other co-morbidities 8
Ramagopalan, 2011(England) UK Retrospective cohort Hyperthyroidism ICD-7,8,9-CM 3,707,315 91,913 NA NA 2,187,316 1,519,999 Age, sex, calendar years and region of residence 7
Ramagopalan, 2011(ORLS) UK Retrospective cohort Hyperthyroidism ICD-7,8,9-CM 187,609 NA NA NA 101,309 86,300 Age, sex, calendar years and region of residence 7
Segna, 2016 Switzerland Prospective cohort (Subclinical) hypothyroidism TSH 4.5–19.99 mlU/L 535 52 Median: 75 Median: 74 325 210 Age, sex, previous venous thromboembolism, active cancer 7
Wei, 2020 China Hypothyroidism ICD-9-CM 32,454 48.9 ± 15.4 48.9 ± 15.4 5835 26,619 Age, sex, income level and other co-morbidities 8
Zaane, 2010 Netherlands Case-control (Subclinical) hyperthyroidism/hypothyroidism Medical records 569 190 Median: 57 Median: 56 240 329 NA 7
Zoller, 2012 Sweden Retrospective cohort Hyperthyroidism ICD-7,8,9,10-CM 50,954 NA NA NA 147,802 174,191 Age, sex, period and other co-morbidities 7
BMI = body mass index, NA = not available, NOS = Newcastle-Ottawa Score

3.3. Quality evaluation

Newcastle-Ottawa Score scores were employed to assess the included studies, with the majority of studies (13 studies in 9 articles) being high-quality studies (score ≥ 7.0) and only 2 studies in 1 article[20] considered of moderate quality (NOS score 5). Quality scores for the included studies are presented in Supplemental Digital Content (Table S2A,B,

3.4. Data analysis

3.4.1. Pooled results of (subclinical) hyperthyroidism.

In the 8 studies involving (subclinical) hyperthyroidism, we pooled the VTE risk using a fixed-effects model to compare (subclinical) hyperthyroid patients with euthyroid populations: OR 1.33 (95% CI: 1.29–1.38, I2 = 27.8%, P = .206) (Fig. 2). A sensitivity analysis of the included studies, ignoring 1 study at a time and recalculating the pooled OR for the other studies, indicated that none had a large impact on the results (Fig. 3), suggesting that the pooled results were relatively robust. Then the funnel plot was introduced to detect publication bias, which was not symmetrical (Fig. 4), and there may be publication bias that impacted the results. Further Begg and Egger tests were performed, and the Egger test also suggested publication bias (Begg test = 0.174, Egger test = 0.007). On this basis, we tried to use the trim-and-fill method to recalculate the results, and 5 missing studies were added to make the funnel plot symmetrical (see Fig. 5). After pooling the 5 theoretical studies, the OR was 1.322 (95% CI, 1.278–1.368), which did not substantially change from the previous result.

Figure 2.:
Forest plot of (subclinical) hyperthyroidism and risk of VTE for all included studies (fixed effect model). VTE = venous thromboembolism.
Figure 3.:
The sensitivity analysis of (subclinical) hyperthyroidism and risk of VTE for all included studies. VTE = venous thromboembolism.
Figure 4.:
The funnel plot of (subclinical) hyperthyroidism and risk of VTE for all included studies. VTE = venous thromboembolism.
Figure 5.:
Funnel plots following trim-and-fill.

3.4.2. Pooled results of (subclinical) hypothyroidism.

In the 7 studies involving (subclinical) hypothyroidism, the random-effects model was used to pool the VTE risk results: OR 1.52 (95% CI: 1.23–1.89, I2 = 99.9%, P = .00) (Fig. 6). We found large heterogeneity in this pooled result, and sensitivity analysis suggested that the results were largely impacted by 2 studies conducted by Danesce, 2009[20] (Fig. 7). Removing the 2 studies resulted in no significant change in results but led to a clear decrease in heterogeneity (including Danesce, 2009: OR 1.52 [95% CI: 1.23–1.89, I2 = 99.9%, P = .00]; excluding: OR 1.74 [95% CI: 1.41–2.16, I2 = 7.1%, P = .366]). We believe that Danesce’s study only selected diagnostic codes extracted from patient discharge information as raw data and was not adjusted by other confounding factors when calculating the RR value. The NOS score of the 2 studies involved in this article indicated that they were of moderate quality. More importantly, the 95% CI range of RR value in this study was narrow, giving the 2 studies heavier weight when the data were pooled. After excluding the 2 studies, the results suggested low heterogeneity. Therefore, Danesce’s[20] studies were the main source of heterogeneity in the results. The funnel plot showed asymmetry (see Fig. 8), and further Begg and Egger tests indicated no publication bias (Begg test = 0.806, Egger test = 0.083).

Figure 6.:
Forest plot of (subclinical) hypothyroidism and risk of VTE for all included studies(random effect model). VTE = venous thromboembolism.
Figure 7.:
The sensitivity analysis of (subclinical) hypothyroidism and risk of VTE for all included studies. VTE = venous thromboembolism.
Figure 8.:
The funnel plot of (subclinical) hypothyroidism and risk of VTE for all included studies. VTE = venous thromboembolism.

4. Discussion

This study is a meta-analysis aiming to evaluate the association between thyroid dysfunction and VTE. There was another meta-analysis investigating the risk of VTE in patients with hyperthyroidism[21] but with some limitations: fewer studies (n = 5) were included, and the associated VTE risk in patients with (subclinical) hypothyroidism was not explored. Therefore, it is necessary to conduct a new meta-analysis to comprehensively assess the association between different types of thyroid dysfunction and VTE.

This meta-analysis found a significantly higher risk of VTE in patients with thyroid dysfunction, in both (subclinical) hyperthyroidism and (subclinical) hypothyroidism, compared with euthyroid individuals. However, the underlying mechanism is still unclear, especially in hypothyroidism, with conflicting study results.

In a meta-analysis investigating coagulation changes in hyperthyroid states, 29 articles, including 51 studies, were included, and the results showed that coagulation factors VIII, IX, von Willebrand factor (vWF), fibrinogen, and plasminogen activator inhibitor-1 (PAI-1) levels were increased in (subclinical) hyperthyroid patients.[22] This may be caused by high levels of thyroid hormone acting directly on hepatocytes and endothelial cells,[23,24] causing patients to be in a hypercoagulable and hypofibrinolytic state for a long time, ultimately leading to venous thrombosis, which is consistent with the conclusions drawn from our analysis. In an observational study, plasma vWF and factor VIII returned to normal values in patients with hyperthyroidism treated with thiamazole,[25] but no studies have further explored changes in the prevalence of VTE after treatment of hyperthyroidism.

In addition, thyroid dysfunction is often strongly associated with autoimmune diseases. Studies have shown that 22% of patients with primary antiphospholipid syndrome have hypothyroidism.[26] In contrast, multiple cohort studies suggest that the prevalence of positive serum antiphospholipid antibodies is also increased in patients with hyperthyroidism,[27,28] and there may be a specific association between thyroid dysfunction and primary antiphospholipid syndrome. Some studies have also discovered that (subclinical) hyperthyroidism and (subclinical) hypothyroidism are both found to be closely related to rheumatoid arthritis.[29] Autoimmune diseases often lead to endothelial cell damage and increase the incidence of VTE. Therefore, this may also factor in the increased risk of VTE in patients with thyroid dysfunction. Gender may also act as an important risk factor for increased VTE risk in patients with thyroid dysfunction. Firstly, female patients are at higher risk of autoimmune diseases,[30] and there is also a higher risk of having thyroid dysfunction along with other autoimmune diseases.[31] In addition, young and middle-aged women often have an increased risk of VTE due to oral contraceptives or bed rest during pregnancy and lower limb blood stasis.[32] Therefore, we found that women with thyroid dysfunction had a higher risk of VTE than men in the included studies,[19] and further large-scale cohort studies are still needed to evaluate further the association between gender and the risk of VTE after thyroid dysfunction in the future.

There are large contradictions in studies related to hypothyroidism and coagulation changes. In early studies, Simone et al[33] found decreased coagulation factor VIII, factor IX, and factor XI levels and corresponding decreased coagulation function in hypothyroid patients. Gullu et al[34] observed coagulation-related factors before and after levothyroxine treatment in 15 patients with hypothyroidism and found that factor VIII and vWF activities in hypothyroid patients were lower than those in the normal population before treatment, and prothrombin time and activated partial thromboplastin time were increased; these coagulation abnormalities could be corrected after 3 months of levothyroxine replacement therapy. In a study of coagulation status in patients with subclinical hypothyroidism, different phenomena were found. A recent meta-analysis of 12 studies with a total of 1325 patients[35] showed that although activated partial thromboplastin time and D-dimer were not significantly different in patients with subclinical hypothyroidism compared with the normal group, tissue plasminogen activator and PAI-1 were higher than those in the normal control group and appeared to have a bidirectional effect on coagulation. The increase of tissue plasminogen activator may be a compensatory reaction of human body after the increase of PAI-1. In conclusion, most studies on coagulation function in hypothyroidism suggest that patients with overt hypothyroidism have a hypocoagulable state and bleeding tendency; while subclinical hypothyroidism may induce a prothrombotic state, PAI-1 may play an important role in it.

In our clinical observational studies based on meta-analysis, both hypothyroidism and subclinical hypothyroidism suggested an increased risk of VTE. Studies[19] have further explored the relative changes in the risk of VTE after thyroid hormone replacement therapy: ①The risk of VTE in hypothyroid people using thyroid hormone replacement therapy remains high compared with people without hypothyroidism (HR: 1.54 [1.17–2.04]), but the risk is lower compared with hypothyroid patients without thyroid hormone replacement therapy (HR: 0.73 [0.52–1.01]). This supports the notion that hypothyroid patients are at increased risk of VTE, and hormone replacement therapy effectively reduces this risk.

In addition to the above factors causing damage to vascular endothelial cells in patients with thyroid dysfunction often associated with autoimmune-related diseases, blood stasis may also be one of the risk factors for increased risk of VTE in hypothyroid patients, and hypothyroid patients often have myxedema, which leads to venous blood stasis. It has been shown that myxedema is considered to be one of the risk factors for VTE.[11] Therefore, although patients with overt hypothyroidism have decreased coagulation and increased bleeding risk, the risk of VTE remains increased under the influence of other combined factors. Prophylactic anticoagulant therapy for high-risk VTE patients with hypothyroidism requires additional vigilance for the risk of bleeding during clinical diagnosis and treatment.

Studies have shown that thyroid dysfunction is often closely related to the prognosis of VTE. Analysis of Pohl et al[36] on the short-term and long-term outcomes in 831 patients with pulmonary embolism showed that hyperthyroidism increased in-hospital mortality in patients with pulmonary embolism. In contrast, in long-term follow-up, both hyperthyroidism and hypothyroidism were associated with an increased risk of long-term mortality. In a chronic thromboembolic pulmonary hypertension (CTEPH) study, thyroid hormone replacement therapy in hypothyroid patients appeared to lead to an increased proportion of CTEPH,[37] and hypothyroid patients with CTEPH have more severe clinical symptoms, higher NT-proBNP and lower cardiac index than those without CTEPH,[38] of which the mechanism is still unclear, and further studies are needed to elucidate their association. Nevertheless, current observational evidence suggests that early diagnosis and treatment of thyroid dysfunction are important in clinical VTE prevention and prognosis.

There are 2 points worth noting in this study, the funnel plot of VTE risk in (subclinical) hyperthyroid patients was initially not symmetrical, and the Egger test suggested publication bias. There was no substantial effect on the results after supplementing 5 theoretical studies with the trim-and-fill method. Therefore, our finding is still significant even in the presence of publication bias. In the VTE risk analysis of (subclinical) hypothyroidism, Danesce’s studies[20] had a major impact on the pooled results. Not only was the study of low quality (NOS score = 5), but it also accounted for a large weight in the pooled analysis, resulting in a significant heterogeneity of the results. After excluding the 2 studies of this article, the results were robust and only suggested mild heterogeneity. The conclusion was consistent with or without Danesce’s studies, indicating an increased risk of VTE in (subclinical) hypothyroid patients.

This study has several limitations. Firstly, patients with thyroid dysfunction are often associated with other symptoms or diseases due to hormonal disturbances, and the included studies did not systematically count data on other potential risk factors for VTE (e.g., obesity, estrogen therapy/contraception, immobilization, etc.), which may limit the accuracy of confounding factor adjustment in multivariate analysis. Secondly, the definition of thyroid dysfunction differed among the included studies, and there was insufficient data to distinguish subclinical thyroid dysfunction from overt thyroid dysfunction, which may have led to a slight bias in the results. More clinical studies are needed to confirm our conclusions in the future.

5. Conclusion

In conclusion, this literature review-based meta-analysis suggests that patients with 2 opposite types of thyroid dysfunction ([subclinical] hyperthyroidism [subclinical] hypothyroidism) both have an increased risk of VTE. Therefore, routine thyroid function screening in patients at high risk for VTE is warranted in clinical practice.

Author contributions

Conceptualization: Yunmeng Wang, Jingru Wang.

Data curation: Yunmeng Wang, Chaowei Ding.

Formal analysis: Yunmeng Wang.

Investigation: Yunmeng Wang, Chang Guo.

Methodology: Yunmeng Wang, Chaowei Ding.

Visualization: Yunmeng Wang.

Writing – original draft: Yunmeng Wang.

Writing – review & editing: Suyun Liu.


chronic thromboembolic pulmonary hypertension
Newcastle-Ottawa Score
plasminogen activator inhibitor-1
venous thromboembolism
von Willebrand factor


[1]. Stone J, Hangge P, Albadawi H, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther. 2017;7(Suppl 3):S276–84.
[2]. Cohen AT, Tapson VF, Bergmann JF, et al.; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371:387–94.
[3]. Elmlinger MW, Kühnel W, Lambrecht HG, et al. Reference intervals from birth to adulthood for serum thyroxine (T4), triiodothyronine (T3), free T3, free T4, thyroxine binding globulin (TBG) and thyrotropin (TSH). Clin Chem Lab Med. 2001;39:973–9.
[4]. Ordookhani A, Burman KD. Hemostasis in overt and subclinical hyperthyroidism. Int J Endocrinol Metab. 2017;15:e44157.
[5]. Ordookhani A, Burman KD. Hemostasis in hypothyroidism and autoimmune thyroid disorders. Int J Endocrinol Metab. 2017;15:e42649.
[6]. Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
[7]. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
[8]. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1–30.
[9]. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
[10]. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.
[11]. Ramagopalan SV, Wotton CJ, Handel AE, et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011;9:1.
[12]. Dekkers OM, Horváth-Puhó E, Cannegieter SC, et al. Acute cardiovascular events and all-cause mortality in patients with hyperthyroidism: a population-based cohort study. Eur J Endocrinol. 2017;176:1–9.
[13]. Lerstad G, Enga KF, Jorde R, et al. Thyroid function, as assessed by TSH, and future risk of venous thromboembolism: the Tromsø study. Eur J Endocrinol. 2015;173:83–90.
[14]. Lin HC, Yang LY, Kang JH. Increased risk of pulmonary embolism among patients with hyperthyroidism: a 5-year follow-up study. J Thromb Haemost. 2010;8:2176–81.
[15]. Zöller B, Li X, Sundquist J, et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379:244–9.
[16]. Hizkiyahu R, Badeghiesh A, Baghlaf H, et al. Associations between hyperthyroidism and adverse obstetric and neonatal outcomes: a study of a population database including almost 17,000 women with hyperthyroidism. Clin Endocrinol (Oxf). 2022.
[17]. van Zaane B, Squizzato A, Huijgen R, et al. Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study. Blood. 2010;115:4344–9.
[18]. Segna D, Méan M, Limacher A, et al. Association between thyroid dysfunction and venous thromboembolism in the elderly: a prospective cohort study. J Thromb Haemost. 2016;14:685–94.
[19]. Wei WT, Liu PPS, Lin SM, et al. Hypothyroidism and the risk of venous thromboembolism: a nationwide cohort study. Thromb Haemost. 2020;120:505–14.
[20]. Danescu LG, Badshah A, Danescu SC, et al. Venous thromboembolism in patients hospitalized with thyroid dysfunction. Clin Appl Thromb Hemost. 2009;15:676–80.
[21]. Srisawat S, Sitasuwan T, Ungprasert P. Increased risk of venous thromboembolism among patients with hyperthyroidism: a systematic review and meta-analysis of cohort studies. Eur J Int Med. 2019;67:65–9.
[22]. Stuijver DJF, van Zaane B, Romualdi E, et al. The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. Review. Thromb Haemost. 2012;108:1077–88.
[23]. Shih CH, Chen SL, Yen CC, et al. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinology. 2004;145:2804–14.
[24]. Debeij J, van Zaane B, Dekkers OM, et al. High levels of procoagulant factors mediate the association between free thyroxine and the risk of venous thrombosis: the MEGA study. J Thromb Haemost. 2014;12:839–46.
[25]. Homoncik M, Gessl A, Ferlitsch A, et al. Altered platelet plug formation in hyperthyroidism and hypothyroidism. J Clin Endocrinol Metab. 2007;92:3006–12.
[26]. de Carvalho JF, Caleiro MT. Primary antiphospholipid syndrome and thyroid involvement. J Clin Rheumatol. 2010;16:164–7.
[27]. Mankaï A, Melayah S, Bousetta S, et al. Antiphospholipid antibodies in autoimmune thyroid diseases. J Clin Lab Anal. 2022;36:e24788.
[28]. Paggi A, Caccavo D, Ferri GM, et al. Anti-cardiolipin antibodies in autoimmune thyroid diseases. Clin Endocrinol (Oxf). 1994;40:329–33.
[29]. Liu YJ, Miao HB, Lin S, et al. Association between rheumatoid arthritis and thyroid dysfunction: a meta-analysis and systematic review. Front Endocrinol (Lausanne). 2022;13:1015516.
[30]. Bartz JA. Oxytocin, attachment, betrayal and self-interest: a commentary on “Oxytocin modulates the link between adult attachment and cooperation through reduced betrayal aversion” by Carsten K.W. De Dreu, Psychoneuroendocrinology, doi:10.1016/j.psyneuen.2011.10.003. Psychoneuroendocrinology. 2012;37:1106–8.
[31]. Martinez JA, Qeadan F, Burge MR. Hypothyroidism, sex, and age predict future thromboembolic events among younger people. J Clin Endocrinol Metab. 2020;105:e1593–600.
[32]. Scheres LJJ, van Hylckama Vlieg A, Cannegieter SC. Sex-specific aspects of venous thromboembolism: what is new and what is next? Res Pract Thromb Haemost. 2022;6:e12722.
[33]. Simone JV, Abildgaard CF, Schulman I. Blood coagulation in thyroid dysfunction. N Engl J Med. 1965;273:1057–61.
[34]. Gullu S, Sav H, Kamel N. Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism. Eur J Endocrinol. 2005;152:355–61.
[35]. Xu Q, Wang Y, Shen X, et al. The effect of subclinical hypothyroidism on coagulation and fibrinolysis: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:861746.
[36]. Pohl KR, Hobohm L, Krieg VJ, et al. Impact of thyroid dysfunction on short-term outcomes and long-term mortality in patients with pulmonary embolism. Thromb Res. 2022;211:70–8.
[37]. Dodson MW, Cirulis MM, Li H, et al. Frequency of thrombotic risk factors in patients with chronic thromboembolic pulmonary hypertension and acute pulmonary embolism: a case-control study. Clin Appl Thromb Hemost. 2022;28:10760296211073277.
[38]. Krieg VJ, Hobohm L, Liebetrau C, et al. Risk factors for chronic thromboembolic pulmonary hypertension – importance of thyroid disease and function. Thromb Res. 2020;185:20–6.

hyperthyroidism; hypothyroidism; meta-analysis; thyroid dysfunction; venous thromboembolism

Supplemental Digital Content

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.